The alarming rise of morbidity and mortality caused by influenza pandemics and epidemics has drawn attention worldwide since the last few decades. This lifethreatening problem necessitates the development of a safe and effective vaccine to 
the two strains of type B. Quadrivalent influenza vaccines were developed during 2013-14 influenza season in the United States and contain the same A strains and two strains of influenza B lineages. 1 These vaccines have high intrinsic immunogenicity that makes them effective against pandemic. 2, 3 International surveillance is performed annually by the World Health Organization 4 to choose appropriate virus strains for inclusion in seasonal influenza vaccines. These selected strains provide HA and NA genes for reassortant vaccine viruses, which also possess internal genes from A/Puerto Rico/8/34 (PR8). PR8 is a strain that confers high viral yield in embryonated eggs. Formalin or β-propiolactone is used to inactivate influenza viruses. Thiomersal or formaldehyde is used in vaccines as a preservative in order to inhibit bacterial or fungal growth. Some manufacturers may also use aminoglycoside antibiotics.
Some vaccines contain additives like gelatine to stabilize them in unfavorable conditions. Residual egg proteins are also present in low quantities in egg-derived inactivated vaccines. 5, 6 Although virus multiplication on embryonated chicken eggs remains the most common method for production of influenza vaccines, it contains several limitations. For instance, securing sufficient qualified eggs for mass vaccine production of the vaccine is very challenging, especially in context of influenza outbreak among poultry. 7 Furthermore, optimization of influenza wild type strains for growth in eggs requires recombination of these strains with high-yield laboratory strains. Thereupon, mutations in the egg-adapted reassortant strain can contribute to a mismatch between the vaccine strain and the circulating strain which was reported recently. IgG especially IgG1 (high concentration), IgA, and IgM (low concentration) are detectable 2 to 6 days post-vaccination and peak 2 to 3 weeks after vaccination in primed subjects. 9-13 Upon vaccination, antibody production is typically type specific. However, it can be highly cross-reactive which results in protection towards earlier and newer viral strains. 14, 15 It has been shown that Influenza inactivated vaccines up-regulate three activation markers of MHC II (CD40, CD80, and CD86), while exposure to active virus and subunit (SU) vaccine has a less similar effect on CD86 expression. Studies show that treatment of DCs with SU vaccines results in similar levels of IL-6 and TNFα. In contrast, in influenza attenuated vaccine (AV) and IV-treated DC cultures, IL-6
and TNFα levels were clearly increased. 16 Live or inactivated influenza virus can induce production of IFN-α and inflammatory cytokines from plasmacytoid DC (pDCs) in a Toll-like receptor (TLR7) and MyD88-dependent manner by recognition of viral single-stranded RNA virus (ssRNA). 17 Signaling of TLR7 in pDCs has an important role in inducing productive antibody response by virion RNA-containing split vaccine 18 and inactivated whole virus vaccine. 19 Conversely, following influenza virus infection in the lungs, cytokine production did not require TLR7-signaling in pDCs. 20 Similar to live viral vaccines, the live attenuated influenza vaccine (LAIV) induces the expression of several interferon-related genes.
Whereas, the TIV vaccine induces a signature composed of genes highly expressed in plasma B cells. In the case of TIV, there are 44 genes identified to accurately predict the outcome of immunization as either high or low antibody titres. Of these, the calcium/calmodulin-dependent protein kinase IV (CaMKIV) gene has no known role in regulating immunity, but has a negative correlation with antibody titres. In agreement with this finding, high antibody titres were observed in the CAMKIV-deficient mice after vaccination. 21 There are comprehensive data about safety properties of inactivated influenza vaccines. Soreness at the vaccination site is a very common local reaction. These kinds of reactions are self-limiting and require no intervention. Systemic reactions such as fever, headache, myalgia, or any physical unease happen mostly in children and due to initial exposure to influenza vaccine antigens. These mild adverse events (AEs) are found within 6 to 12 hours postimmunization and last for 1 to 2 days. 22 Figure 2 and Table 1 antigens of the influenza A virus. The main disadvantage of this recombinant SU vaccine is low immunogenicity; therefore, the need for repeated vaccination and use of adjuvants are recommended. 39, 40 As mentioned, use of adjuvants in the composition of SU vaccines can resolve this problem. AEs and the vaccine seemed to be well-tolerated and safe enough. This method of VLP production is considered safer than other expression systems. 59 Another clinical trial also has evaluated a VLP vaccine produced by the same method and side effects were mostly mild. However, adjuvanted VLP vaccine could raise local and systemic reactions. 60 Also, a phase I clinical trial on previously healthy non-immune adults exhibited remarkable safety results for a bacterially produced VLP vaccine (gH1-Qbeta). Most of the reported local and systemic AEs were mild in severity and no serious AEs were occurred. localization to the trans-Golgi network is important for NLRP3 activation. 79 Due to lacking its proton selectivity, the mutant influenza virus M2 protein enables the transport of other cations (Na + and K + ), which mediates increased IL-1β secretion compared with the wildtype M2 protein. 79 An acceptable safety profile has been revealed for these vaccines.
ACAM-FLU-A,a M2e_HBc vaccine manufactured by Sanofi Pasteur
was tested in phase I clinical trial and showed no serious side effects. 80 STF2.4xM2e, M2e vaccine with flagellin as an adjuvant, was reported to be safe, but two high doses of the vaccine were observed to be associated with raised levels of C-reactive protein (CRP). 81 Another universal influenza vaccine, Multimeric-001, was
announced to be safe in phase I/II clinical trial, and no severe AE was reported. and CD8 T cells. 92 An immunodominant CTL vaccine epitope is likely to reduce the extent of response in primed vaccinated subjects. Thus, epitope choice can also alter the outcome of the response, depending on the binding avidity of the T-cell antigen receptors (TCRs) with the MHC peptide. 93 For a strong CD8 T-cell response, the antigen should be processed via the MHC class I processing pathway of dendritic cells (DCs). During infection, the viral antigen is loaded onto DCs by direct entry of the virus or through uptake of infected cells undergoing apoptosis. 94 Hence, CTL responses during vaccination are different.
In other words, LAIV induces a strong CD8 T-cell response, while the conventional SU TIV is less effective than the whole-virus vaccine at inducing CTLs. 90 Thus, taking all of these considerations is needed in the successful design and execution of a CTL-based vaccination approach. Third, production: mRNA vaccines are capable of being produced in a rapid, cheap, and scalable manner, mainly because of the high yields of in vitro transcription reactions. 96 As toxic chemicals are not used in manufacturing of mRNA, there is no possibility of common risks associated with other vaccine platforms. 95 However, possible undesired consequences such as fever can originate from the extreme induction of type I interferons and proinflammatory cytokines, mediated by some RNA vaccines. Also, extracellular RNA arisen from vaccine may result in safety concerns via mediating the formation of pathological thrombus or edema. 97 Despite the good antiviral protection, mRNA vaccines require a great amount of synthetic mRNA material, probably limiting the accessibility of vaccine in cases of epidemics and pandemics. Owing to the greater length of constructed products, challenges remained to be addressed in terms of the production process and stability of the mRNA products, especially with selfamplifying RNA vaccines. 9 | MICRORNA AND EXOSOME-BASED VACCINE
MicroRNAs are small non-coding RNAs which act as epigenetic regulators. [99] [100] [101] [102] [103] [104] [105] [106] These molecules play critical roles in regulation of gene expression in the RNA and protein levels. 22, [107] [108] [109] [110] [111] [112] [113] It has been shown that deregulation of microRNAs is associated with initiation and progression of various diseases such as infectious diseases, cardiovascular diseases, diabetes, neurogenerative diseases, and cancer. 112, Exosomes are other particles which have critical roles in the pathogenesis of various diseases. 122, [135] [136] [137] Exosomes are nano-carriers which carry many cargos such as DNAs, RNAs, microRNAs, LncRNAs, and proteins. Targeting these cargos to host cells could lead to change behaviors of cells and contribute to progression of physiological and pathological processes. 138, 139 As vaccine preparation through classical temperature-based attenuation method was a time-consuming procedure, the need for urgent control of influenza outbreaks emerge from mutant viruses, highlighting the importance of preparing vaccines based on other mechanisms such as (microRNA) miRNA and exosome technologies. 140 MiRNA-based strategy for influenza virus attenuation could act through sequence-specific gene silencing mechanism or using miRNA/siRNA to suppress virus replication or infection.
According to previous studies, inserting miRNA response element pandemic H1N1virus (H1N1) genome successfully produced a recombinant virus which was slow to grow and attenuated in mice respiratory system. 143 Another in vivo study found that incorporating miR-93 target sites into H1N1 and H5N1 viruses could result in viral attenuation in human lines and mouse lungs. 141 Similarly, fusing of miR-192 target sequence into IAV genome could attenuate influenza pathogenicity in mice. 142 Furthermore, the ability of miRNA-based attenuation method to determine virus fitness through introducing various number and location of target sites is superiority over classical viral attenuation methods. 144 Together, these evidences suggested that the engineering flu genome virus containing the target sites of deregulated miRNAs in a species-specific manner could be employed as a highthroughput strategy which is able to provide a new class of flu IAV Future studies can offer more ideal products by assembling the advantages of existing vaccines in a unique influenza vaccine.
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